Welcome to our Medical Assistant preparation and certification program. The program offers a self-paced duration. If you meet all the requirements, you can apply through this pathway and complete the payment. The booking section allows you to schedule a call where we’ll provide essential information for your certification process. To ensure eligibility, please visit our services page. Feel free to ask if you need further assistance! 😊

Join our 1-hour BLS course to learn how to recognize life-threatening emergencies, perform high-quality chest compressions, deliver ventilations, and use an AED effectively. Taught according to the latest American Heart Association guidelines. 🩺🌟 For more details, you can visit the Service Page. If you have any other questions, feel free to ask! 😊 What does this course teach? High-quality CPR for adults, children, and infants The AHA Chain of Survival, specifically the BLS components Important early use of an AED Effective ventilations using a barrier device Importance of teams in multirescuer resuscitation and performance as an effective team member during multirescuer CPR Relief of foreign-body airway obstruction (choking) for adults and infants

Welcome to our Surgical Assistant preparation and certification program. The program offers a self-paced duration. If you meet all the requirements, you can apply through this pathway and complete the payment. The booking section allows you to schedule a call where we’ll provide essential information for your certification process. To ensure eligibility, please visit our services page. Feel free to ask if you need further assistance! 😊

In the relentless battle against cancer, one of the biggest challenges is the tumor's ability to defend itself. Cancer cells often develop protective barriers or employ tiny "efflux pumps" that expel life-saving drugs, making many chemotherapies ineffective. However, a recent wave of studies introduces a new and powerful strategy to physically break down these defenses: magnetic nanorobots in cancer treatment . Scientists have developed several types of these minuscule robots, designed to be guided by external magnetic fields for highly precise drug delivery deep into tumor tissues. One particularly innovative design features spiky nanorobots, which act like "microscopic scalpels" . These robots, roughly 200 times thinner than a human hair, are constructed with gold nanospikes coated in nickel for magnetic control and titanium for safety. When guided to a tumor and spun by a magnetic field, their sharp spikes physically pierce the cancer cell's membrane. This disruption creates tiny pores, giving chemotherapy drugs a direct shortcut into the cell and bypassing its resistance mechanisms. The results from laboratory and animal studies are remarkably promising. In experiments on human liver, cervical, and colon cancer cells, the nanorobots significantly increased the uptake of the chemotherapy drug doxorubicin. More impressively, when tested on mice with liver tumors, the combination of nanorobots and chemotherapy led to a 61% reduction in tumor growth and a 100% survival rate  for the treated group, with minimal side effects. Other studies confirm these bionic nanorobots enhance drug delivery, lower toxicity, and can even activate the body's own tumor immune response. Researchers describe this as a "dual approach," where the robots not only improve drug uptake but also directly damage cancer cells through a process called "mechano-killing". This combination of mechanical disruption and targeted chemotherapy represents a potent new direction for oncology. While this groundbreaking technology is still in its early stages and requires further refinement before human trials can begin, it marks a significant step forward. By creating a way to physically cut through cancer's shield, scientists have opened new possibilities for safer, more precise therapies that could one day overcome even the most drug-resistant tumors. 🔖 Sources Magnetically-powered nanorobots enhance drug uptake in tumors Magnetically driven bionic nanorobots enhance chemotherapeutic efficacy and the tumor immune response via precise targeting Self-propelling, protein-bound magnetic nanobots for efficient in vitro drug delivery in triple negative breast cancer cells Advancements in Micro/Nanorobots in Medicine: Design, Actuation, and Transformative Application

In the annals of pharmaceutical history, few stories are as dramatic, explosive, and polarizing as that of Moderna. For years, it was a highly secretive and speculative biotech startup, built on the audacious promise of a revolutionary new technology: messenger RNA (mRNA). Then, in 2020, the COVID-19 pandemic hit, and Moderna was catapulted onto the global stage. In a historic feat of science and speed, the company developed one of the world's leading COVID-19 vaccines, saving millions of lives and generating tens of billions of dollars in revenue almost overnight. This unprecedented success turned Moderna into a household name and a stock market phenomenon. But the pandemic-fueled boom is now over. COVID vaccine sales have plummeted, and Moderna now faces the monumental challenge of proving that it is not a one-hit wonder. The company is in a high-stakes race to translate the proven power of its mRNA platform into a new wave of vaccines and therapies for a wide range of diseases, from RSV and the flu to cancer and rare genetic disorders. For investors, this makes Moderna one of the most compelling and high-risk, high-reward opportunities in the entire market. Is this the dawn of a new era of medicine, led by a true platform company? Or is the stock an overvalued remnant of a pandemic bubble? This in-depth analysis will dissect the investment case for the pioneer of mRNA technology. Content⁉️ 1️⃣ A Legacy of Scientific Revolution 2️⃣ The Modern Moderna (MRNA): Building a Post-COVID Pipeline 3️⃣ Financials: A War Chest for Innovation 4️⃣ The Investment Thesis: Weighing the Pros and Cons 5️⃣ Fundamental Data 🔖 Key Takeaways A Legacy of Scientific Revolution Moderna was founded in 2010 with a vision that was both simple and breathtakingly ambitious. The central idea was to use messenger RNA—the molecule that carries genetic instructions from DNA to the cell's protein-making machinery—as a new class of medicine. In essence, the company's founders believed they could turn the human body into its own drug factory. The concept is revolutionary. Instead of manufacturing complex biologic drugs in massive industrial bioreactors, Moderna could simply design a strand of mRNA with the right genetic code. When injected into the body, this mRNA would instruct the patient's own cells to produce a specific protein—either a therapeutic protein to treat a disease or a viral antigen to train the immune system. For its first decade, Moderna operated largely in "stealth mode," raising huge amounts of private capital to build out its platform and pipeline. The scientific community was intrigued but skeptical. The central challenge was figuring out how to deliver the fragile mRNA molecules into human cells without them being destroyed by the body's natural defenses. Moderna's key breakthrough was its development of lipid nanoparticle (LNP) delivery technology, which acts as a protective bubble to carry the mRNA to its target. This foundational work laid the groundwork for its historic response to the COVID-19 pandemic. When the genetic sequence of the SARS-CoV-2 virus was published, Moderna's platform allowed it to design a vaccine candidate in a matter of days. The subsequent success of its COVID-19 vaccine, Spikevax, provided the ultimate validation of its mRNA technology and turned the company into a commercial powerhouse. The Modern Moderna (MRNA): Building a Post-COVID Pipeline With the pandemic now in the rearview mirror, Moderna’s entire strategy is focused on leveraging its validated platform and its massive cash hoard to deliver on its long-held promise of creating a new class of medicines. The company is advancing a deep and diverse pipeline across multiple therapeutic areas, with a near-term focus on respiratory vaccines. 1. The Respiratory Vaccine Franchise: The Next Commercial Engine This is the most important near-term driver for the company. Moderna’s goal is to become the dominant player in the adult respiratory vaccine market by developing a portfolio of highly effective, best-in-class mRNA vaccines. RSV Vaccine (mRESVIA):  In 2024, Moderna launched its first new major product since the COVID vaccine: mRESVIA, for the prevention of respiratory syncytial virus (RSV) in older adults. This is a multi-billion-dollar market, and Moderna is competing directly with established giants like GSK and Pfizer. Flu Vaccine:  The company has a next-generation seasonal flu vaccine in late-stage development. The key advantage of the mRNA platform is that it can be updated much more quickly than traditional egg-based vaccines, potentially allowing for a better match to the circulating flu strains each season. COVID-Flu-RSV Combination Vaccine:  This is the ultimate goal. A single, annual booster shot that protects against the three biggest respiratory threats is seen as a massive commercial opportunity that would offer unparalleled convenience for patients and providers. This combination vaccine is already in late-stage clinical trials. 2. The Oncology and Rare Disease Moonshots Beyond respiratory diseases, Moderna is pursuing a series of high-risk, high-reward programs in more complex therapeutic areas. The Personalized Cancer Vaccine (PCV):  This is the most exciting and speculative part of the pipeline. In partnership with Merck, Moderna is developing a fully individualized cancer vaccine. The process involves sequencing a patient's tumor, using AI to identify unique mutations, and then creating a custom mRNA vaccine that teaches the patient's own immune system to recognize and destroy their specific cancer cells. Early data in melanoma, when combined with Merck’s KEYTRUDA, has been highly promising. If successful, this would be a paradigm shift in cancer treatment. Rare Genetic Diseases:  Moderna is also developing mRNA therapies for a range of rare metabolic diseases, where the goal is to use mRNA to instruct the body to produce a missing or defective protein. Financials: A War Chest for Innovation Moderna’s financial situation is unique. The success of Spikevax has left the company in an incredibly strong financial position, but its future revenue stream is highly uncertain. Massive Cash Position:  Moderna is sitting on a "war chest" of over $15 billion  in cash and investments. This immense financial firepower gives it a long runway to fund its ambitious and costly R&D pipeline for years to come without needing to raise additional capital. The Post-COVID Revenue Cliff:  This is the company's biggest challenge. Revenue has fallen from a peak of over $19 billion in 2022 to an expected $4-5 billion in 2025, driven by the collapse in COVID vaccine sales. The company's future revenue will depend entirely on the successful commercial launches of its new vaccines for RSV and the flu, and the long-term success of its oncology and rare disease pipeline. No Debt, No Dividend:  Moderna has a pristine balance sheet with no debt. As a high-growth, R&D-focused biotech, it does not pay a dividend. Every dollar of profit and cash is being reinvested back into the business to fund the pipeline. The stock’s valuation is highly volatile and is driven almost entirely by sentiment around its pipeline and the perceived potential of its mRNA platform. The Investment Thesis: Weighing the Pros and Cons When analyzing Moderna, the investment case is a clear-cut and high-stakes debate between a revolutionary technology platform with world-changing potential and the immense uncertainty that comes with a company almost entirely dependent on its future pipeline. The Bull Case: Why Invest in Moderna? The argument for investing in Moderna is a bet on the power of its revolutionary mRNA platform technology . This is not just a single-drug company; it's a company with a proven, best-in-class technological engine that has the potential to create a new class of medicines across a wide range of diseases. This potential is reflected in its deep and diverse R&D pipeline , which includes dozens of programs with the potential for paradigm-shifting therapies , most notably the personalized cancer vaccine. This ambitious pipeline is fully funded by the company's massive cash position and fortress balance sheet , a war chest that gives it a long runway for innovation without financial pressure. Finally, the company's proven scientific and execution capabilities , demonstrated by its historic achievement with the COVID-19 vaccine, provide a level of confidence in its ability to deliver on its ambitious goals. The Bear Case: Reasons for Caution Conversely, the reasons for caution are significant and clear. The most immediate challenge is the extreme post-COVID revenue decline . With sales of its only commercial product having collapsed, the company is entirely dependent on its unproven pipeline, which carries high clinical and commercial risk . There is no guarantee that its new vaccines for RSV and flu will be commercially successful against intense competition  from entrenched giants like Pfizer and GSK. This total reliance on future events leads to extreme valuation uncertainty , making the stock highly volatile and difficult to value based on traditional metrics. As a pure, speculative bet on future R&D success, the company has no dividend or significant current earnings  to provide a floor for the stock, making it unsuitable for conservative investors. Fundamental Data Go beyond the stock price with this deep dive into a company's core fundamentals. 🔖 Key Takeaways The decision to invest in Moderna is a decision to make a high-risk, high-reward bet on the future of medicine. It is an investment in a revolutionary technology platform and a deep pipeline of ambitious, but unproven, new products. For the Aggressive, High-Risk Growth Investor:  Moderna represents a unique opportunity. You are investing in a company that has already validated a Nobel-prize-worthy technology platform and now has the capital to fully exploit its potential. The bull thesis is that even if only a few of its pipeline candidates succeed—particularly the combination respiratory vaccine or the personalized cancer vaccine—the upside could be astronomical. This investor must have a very long time horizon and a high tolerance for the extreme volatility that comes with biotech R&D. For the Conservative, Value, or Income Investor:  This stock is entirely unsuitable. The lack of current profitability, the absence of a dividend, and the speculative, binary nature of its pipeline are all direct contradictions to a conservative investment philosophy. Moderna is one of the most exciting and consequential companies in the world of biotechnology. It has the technology, the talent, and the capital to potentially change the face of medicine for a second time. However, the path from a single, pandemic-driven success to a diversified, sustainably profitable biopharmaceutical company is long and fraught with risk. An investment in Moderna today is not a bet on what the company is, but on what it could one day become. This was the Moderna (MRNA) Stock: A Biotech Pioneer's High-Stakes Quest to Revolutionize Medicine. Want to know which healthcare stocks are part of the S&P 500? Click here .

In the high-stakes world of biotechnology, where fortunes are made and lost on the success of a single clinical trial, few companies have achieved the level of scientific and commercial success that Regeneron Pharmaceuticals has. This is not a company built on marketing savvy or financial engineering; it is a pure, unadulterated science story. For over three decades, Regeneron has been a model of R&D excellence, leveraging its proprietary technologies to build a pipeline of blockbuster drugs that have transformed the treatment of major diseases. The company's immense success is overwhelmingly concentrated in two mega-blockbuster drugs: EYLEA for eye diseases and Dupixent for allergic conditions. These two products have turned Regeneron into a cash-generating machine with one of the most profitable and admired businesses in the entire biopharma industry. But this incredible success is also the source of its greatest risk. With a portfolio heavily dependent on just two products, one of which is now facing biosimilar competition, investors are asking a critical question: Can Regeneron's legendary R&D engine produce the next wave of blockbusters to carry the company into the future? This in-depth analysis will dissect the investment case for this science-driven biotech powerhouse. Content⁉️ 1️⃣ A Legacy of Scientific Prowess 2️⃣ The Modern Regeneron (REGN): A Tale of Two Blockbusters 3️⃣ Financials: A High-Margin, Cash-Rich Innovator 4️⃣ The Investment Thesis: Weighing the Pros and Cons 5️⃣ Fundamental Data 🔖 Key Takeaways A Legacy of Scientific Prowess Regeneron was founded in 1988 by a pair of brilliant scientists, Dr. Leonard Schleifer and Dr. George Yancopoulos. From its inception, the company's strategy has been guided by a single, unwavering principle: follow the science. Unlike many of its peers, Regeneron has consistently prioritized long-term, ambitious R&D projects over short-term commercial gains. This science-first culture has led to the development of a suite of proprietary, best-in-class drug discovery and development technologies, most notably the VelocImmune®  mouse. This is a genetically engineered mouse that has a humanized immune system, allowing Regeneron to rapidly and efficiently discover highly effective, fully human antibodies that can be turned into drugs. This technology is a massive competitive advantage and the engine behind nearly all of the company's most successful products. The company’s history is defined by a series of major scientific and commercial breakthroughs: EYLEA (aflibercept):  Launched in 2011, this was Regeneron’s first mega-blockbuster. It is the gold standard for treating a range of retinal diseases, most notably wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), which are leading causes of blindness. Praluent (alirocumab):  One of the first PCSK9 inhibitors for lowering cholesterol. Dupixent (dupilumab):  Launched in 2017, this drug has become a revolutionary treatment for a range of allergic or "type 2 inflammatory" diseases, including atopic dermatitis (eczema), asthma, and more. Its success has been nothing short of phenomenal. Libtayo (cemiplimab):  An immunotherapy drug for treating certain types of cancer, particularly advanced cutaneous squamous cell carcinoma. This history of consistent, internally-driven R&D success is the foundation of the investment case for Regeneron. It is a bet that the company’s powerful scientific engine will continue to produce winners. The Modern Regeneron (REGN): A Tale of Two Blockbusters To understand Regeneron today, you must understand the two products that are the pillars of its empire. 1. The EYLEA Franchise: The Ophthalmology King For over a decade, EYLEA has been the undisputed king of the ophthalmology market. The drug is an anti-VEGF therapy that works by blocking the growth of abnormal blood vessels in the eye. Dominant Market Position:  EYLEA has been the market-leading treatment for wet AMD and DME for years, generating over $9 billion  in annual global sales at its peak (shared with partner Bayer). The High-Dose Innovation:  To defend its franchise from emerging competition, Regeneron recently launched a new, high-dose version of the drug, EYLEA HD . This new formulation allows patients to be treated less frequently (every 8 to 16 weeks instead of every 4 to 8 weeks), a major quality of life improvement that is helping to protect its market share. The Biosimilar Threat:  However, the original, lower-dose version of EYLEA is now facing the imminent threat of biosimilar competition, which will put significant pressure on sales and profitability for this foundational franchise in the coming years. 2. The Dupixent Juggernaut: A Pipeline in a Product If EYLEA built the house of Regeneron, Dupixent is the rocket engine that is now powering its future. Developed in a highly successful, long-term collaboration with the French pharmaceutical giant Sanofi , Dupixent has become one of the most successful drugs in the world. The drug works by blocking the signaling of two key proteins (IL-4 and IL-13) that are the root cause of several allergic diseases. Its success has been staggering: Massive and Growing Sales:  Dupixent is already a mega-blockbuster with over $12 billion  in annual sales and is still growing at a rapid, 20-30% pace. A "Pipeline in a Product":  The true power of Dupixent is its versatility. It is already approved for five different diseases, and it is in late-stage clinical trials for a host of other potential indications, from chronic obstructive pulmonary disease (COPD) to food allergies. Many analysts believe Dupixent has the potential to become one of the best-selling drugs of all time, with peak sales estimates reaching as high as $25-30 billion. The continued growth of Dupixent is the single most important driver of Regeneron’s near-to-medium-term financial performance. Financials: A High-Margin, Cash-Rich Innovator Regeneron’s scientific success has translated into an incredibly strong and profitable financial profile. High Growth and Profitability:  Driven by the success of EYLEA and Dupixent, the company has a track record of delivering strong revenue growth and some of the highest operating margins in the entire biopharmaceutical industry. Fortress Balance Sheet:  The company has a pristine balance sheet with a massive cash pile (often exceeding $15 billion) and very little debt. This gives it immense financial flexibility to invest heavily in its R&D pipeline and to pursue strategic, "bolt-on" acquisitions. Capital Allocation: R&D and Buybacks:  Regeneron’s capital allocation strategy is squarely focused on innovation. Massive R&D Investment:  The company reinvests a huge portion of its revenue (typically 25-30%) back into its R&D engine, funding the search for the next EYLEA or Dupixent. No Dividend:  Regeneron has never paid a dividend, choosing instead to reinvest all of its profits. Share Repurchases:  The company uses its excess cash flow to opportunistically buy back its own stock. The stock’s valuation typically reflects its status as a best-in-class, blue-chip biotechnology company. REGN often trades at a premium P/E ratio, as the market is willing to pay up for its superior profitability and its proven R&D engine. The Investment Thesis: Weighing the Pros and Cons When analyzing Regeneron, the investment case presents a clear and compelling debate between a world-class scientific engine and the significant risks of a highly concentrated business model. The Bull Case: Why Invest in Regeneron? The primary argument for investing in Regeneron is its best-in-class, science-driven R&D engine . This is a company with a long and proven track record of developing blockbuster drugs internally, a rare feat in the biopharma industry. This scientific prowess is on full display with the Dupixent growth story , one of the most successful drug launches in history, which has a long runway for continued expansion. This success, combined with the foundational dominance of EYLEA, gives the company clear leadership in its core markets  of ophthalmology and type 2 inflammation. This market leadership, powered by a successful long-term partnership  with Sanofi, has resulted in exceptional profitability and financial strength , including some of the highest margins in the industry and a fortress balance sheet with a massive net cash position. The Bear Case: Reasons for Caution Conversely, the most significant risk is the company's extreme product concentration . An overwhelming majority of Regeneron's revenue and profit is dependent on just two drugs, EYLEA and Dupixent. This creates significant portfolio risk, which is amplified by the looming EYLEA patent cliff . The company's foundational product is now facing biosimilar competition, which will create a major revenue and profit headwind in the coming years. To overcome this, the company must rely on its pipeline, which carries the high R&D risk  inherent in all of biotechnology; there is no guarantee the next trial will be a success. Finally, as a high-quality biotech leader, the stock often trades at a premium valuation , and its focus on reinvesting for growth means it pays no dividend , making it unsuitable for income-focused investors. Fundamental Data Go beyond the stock price with this deep dive into a company's core fundamentals. 🔖 Key Takeaways The decision to invest in Regeneron is a decision to bet on the continued success of one of the best scientific teams in the world. It is a pure-play on R&D productivity and innovation. For the Long-Term Growth Investor:  Regeneron is a quintessential "core holding" in the biotechnology sector. You are investing in a company with a proven, best-in-class R&D engine that has already produced two of the most successful drugs of the modern era. The bull thesis is that the massive and growing cash flow from Dupixent will fund the development of the next wave of blockbusters from its deep and promising pipeline. For the Value or Income Investor:  This is not the right stock. The lack of a dividend is an immediate disqualifier for those seeking income. Furthermore, the company’s premium valuation and its reliance on future R&D success are at odds with a traditional, conservative value investing approach. Regeneron Pharmaceuticals is a true biotech blue-chip. The company’s unwavering focus on science has created a business of exceptional quality and profitability. While the risks of its concentrated portfolio and the looming EYLEA patent cliff are significant and should not be ignored, the phenomenal success and continued growth of Dupixent provide a powerful bridge to the future. For investors with a long time horizon and a belief in the power of scientific innovation, Regeneron remains one of the highest-quality investments in the biopharmaceutical industry. This was the Regeneron (REGN) Stock: The Science-Driven Biotech with a Concentrated Fortune. Want to know which healthcare stocks are part of the S&P 500? Click here .

Looking for engaging healthcare videos? Discover clinical demonstrations, expert insights, and viral content, including Sherringford video picks from social media and TV shows. Watch now on our Videoshelf! Swipe down Sherringford TV Our non-stop live stream dedicated to bringing you the latest news, groundbreaking research, career insights, and vital discussions from across the entire healthcare spectrum. Explore More Schedule Use this space to promote the business, its products or its services. Item Title Two Use this space to promote the business, its products or its services. Item Title Three Use this space to promote the business, its products or its services. Latest Recommended Video 3 tips on how to study effectively Explore how the brain learns and stores information, and find out how to apply this for more effective study techniques. Entertainment See list The Pitt 2025 House M.D. 2004 - 2012 Hospital Playlist 2020-2021 Call the Midwife 2012 - Casualty 1900s 2009 The Knick 2014 - 2015 M*A*S*H 1972 - 1983 Doc Martin 2004-2022 This Is Going to Hurt 2022 Scrubs 2001 - 2010 Bodies 2004 - 2006 Northern Exposure 1990 - 1995 The Artful Dodger 2023 St. Elsewhere 1982 - 1988 The Good Doctor 2017 - 2024 Code Black 2015 - 2018 New Amsterdam 2018 - 2022 The Doctor Blake Mysteries 2013-2018 Transplant 2020 - 2024 ER 1994 - 2009 Documentaries See list Being Mortal THE GREAT NHS HEIST First Day As A JUNIOR DOCTOR - Barnsley Hospital Welcomes The Newest Junior Doctors The Cybernetic Future Of Humanity Could AI Become More Intelligent Than Humans? What Happens To The Brain In Old Age? From Castration to Cure: How Scientists Discovered Hormones With Brutal Experimentation Unbelievably Intelligent (Extraordinary People Documentary) Medical Errors Documentary: Why Doctors Make Mistakes Secrets of the Mega Hospital: Inside the Operations of a 24/7 Clinic Most Dangerous Ways To School | Best Of - Peru, Nicaragua & Mexico Most Dangerous Ways To School | Best Of - Philippines, Colombia & Bolivia The Most Bizarre Neurological Conditions You Never Heard Of Making Rounds: Medical Education Getting Better: 200 Years of Medicine Tips See list 3 tips on how to study effectively NCLEX Study Plan 3-Step | NCLEX Review Series Nurse Mike's Tips & Tricks The BEST Way to Study for USMLE Step 1 How to Study Pharmacology in Medical School How to Study Anatomy (in Medical School) Sherringford We designed Sherringford.org to be more than just an educational resource; it's a platform intended to bring a refreshing twist to your daily professional life. Explore Main Pages Home About us Search Pricing Store Points Knowledge Library Blog News Courses Services Community Infotainment MH Colaboration Advertise with us Suggestions Work with us Publish on our blog Publish mentor availability Find a mentor Donations Comply Private Policy Disclosure Terms and Conditions Do Not Sell My Personal Information

Advance your career! Unlock your potential with Sherringford's Healthcare Learning Platform. We curate essential content for professionals & students, driving motivation, growth and expertise in the Healthcare field. +1k followers All Things Healthcare, Curated for You We empower medical, nursing, and other healthcare students with curated and original content across all healthcare topics. We help you gain the knowledge, skills, certification, motivation, and desire for growth you're looking for. Explore Free Log in +100 members Blog: valuable information about anything related to the healthcare field. News: latest updates on critical developments in the healthcare industry. knowledge Library: structured content of academic subjects in medicine. Unleash the fun Our website is designed to bring a refreshing twist to your daily professional life. Dive into engaging content that not only keeps you informed about the latest in healthcare but also adds a dash of excitement to your routine. Click Unleash the fun Our website is designed to bring a refreshing twist to your daily professional life. Dive into engaging content that not only keeps you informed about the latest in healthcare but also adds a dash of excitement to your routine. OUR TEAM You want to change fields and don't know where to start... We provide you with the guidance you need to join and advance in the Health sector, as well as the best resources for your preparation. Explore You want to get certified in new roles to expand your practice... We guide and train you in your certification process. Explore Reach New Heights With our educational support and training services, we offer you a range of possibilities for growth and skill acquisition. Unlock your potential with our comprehensive certification programs in Surgical Assistant, Medical Assistant, and Basic Life Support (BLS). Gain knowledge, skills, motivation, and a desire for growth. Map The BLS certification with Sherringford is excellent, you have mannequins to practice on, and high quality videos to improve your understanding of different situations. Tomas Fuentes Client Review I really liked having a mock exam of the final exam available, I think that made the difference in me passing the Medical Assistant certification exam. Emma Jones Client Review Reliable company, I obtained my AHA accredited BLS certification and my AMT accredited Medical Assistant registration. Both certifications are valid throughout the USA. Carlos Gonzalez Client Review Unlock your potential, grow your opportunities If you are looking for personal contact and detailed information about our services, we invite you to contact us. Our dedicated team is ready to answer your questions, guide you through our offerings, and connect you to the resources you need. Don't hesitate to contact us, your journey to excellence in healthcare education is just a call away. Ask for anything Name Email* Message* Submit Ads help us 💰pay for things like hosting and site 🤑maintenance. 🫀Thanks for helping us keep everything running smoothly so we can continue to provide free content.🫀 Sherringford TV Sherringford We designed Sherringford.org to be more than just an educational resource; it's a platform intended to bring a refreshing twist to your daily professional life. Explore Main Pages Home About us Search Pricing Store Points Knowledge Library Blog News Courses Services Community Infotainment MH Colaboration Advertise with us Suggestions Work with us Publish on our blog Publish mentor availability Find a mentor Donations Comply Private Policy Disclosure Terms and Conditions Do Not Sell My Personal Information 7712 NW 5th St, Plantation, FL 33324 contact@sherringford.org © 2024 by Sherringford LLC.

OWN ending participle Group 3. All three forms of the verb are different Base Form - Simple Past - Past Participle Know knew known Grow grew grown Throw threw thrown Blow blew blown Fly flew flown Show showed shown Back to list English Irregular Verbs Verbs that don't follow regular conjugation patterns. Group 1 OWN ending participle Group 3. All three forms of the verb are different Go Go Sherringford We designed Sherringford.org to be more than just an educational resource; it's a platform intended to bring a refreshing twist to your daily professional life. Explore Main Pages Home About us Search Pricing Store Points Knowledge Library Blog News Courses Services Community Infotainment MH Colaboration Advertise with us Suggestions Work with us Publish on our blog Publish mentor availability Find a mentor Donations Comply Private Policy Disclosure Terms and Conditions Do Not Sell My Personal Information